Today
-0.38%
5 Days
-4.86%
1 Month
-2.50%
6 Months
-7.67%
Year to Date
-1.54%
1 Year
-3.81%
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
By Patrick Wingrove and Bhanvi Satija July 29 (Reuters) - Investors and analysts say they expect Eli Lilly LLY.N to report stronger quarterly sales and profit next week than Danish rival Novo Nordisk NOVOb.CO did on Tuesday, and are anxiously awaiting a full-year outlook and updates on an experim
TradingKey - During a Cabinet meeting at the White House on July 8, Trump announced plans to impose tariffs of up to 200% on imported drugs, requiring pharmaceutical companies to relocate their production chains to the United States and granting them a 1 to 1.5-year adjustment period. If companies..
TradingKey - Just two months into their weight-loss drug partnership, Novo Nordisk (NVO) announced on Monday, June 23, that it is terminating its collaboration with telehealth company Hims&Hers (HIMS). The move sent shockwaves through the market, with shares of the so-called "AI + healthcare" growth
In contrast with the general assumption that Eli Lilly (LLY) is priced for perfection, the Q1 2025 numbers indicate the company's stock is in the nascent stages of a strategic turning point.
Though oncology remains the largest therapeutic area in the pharmaceutical industry, the weight management field has caught fire in the past few years. Eli Lilly (NYSE: LLY) is one of the undisputed leaders in developing anti-obesity medicines, with Novo Nordisk (NYSE: NVO) being its biggest...
.jpg)
WASHINGTON, May 12 (Reuters) - U.S. President Donald Trump signed a wide-reaching executive order on Monday directing drugmakers to lower the prices of their medicines to align with what other countries pay that analysts and legal experts said would be difficult to implement.
